Skip to main content
OpenTrials
Completed

NCT Number: NCT07160998

An Active Health-Based Comprehensive Study on Diabetes Management

This randomized, open-label, multicenter trial evaluates the efficacy and safety of the AI-based lifestyle guidance system (X-Life) compared to standard care in adults with type 2 diabetes. X-Life integrates glucose level, wearable devices, and AI-driven decision models to provide personalized lifestyle recommendations. The primary endpoint is the percentage of time in glucose target range (TIR).

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai Sixth People's Hospital

Shanghai, China

About this study

Type 2 diabetes imposes a global health burden. Traditional care has limitations in accessibility, personalization, and long-term adherence. AI-driven digital therapeutics may overcome these barriers. X-Life is an innovative AI system providing individualized lifestyle guidance using glucose level and wearable data. User studies demonstrated usability and acceptability. This multicenter randomized controlled trial will rigorously test whether X-Life improves glycemic control compared with standard care, while also evaluating metabolic outcomes, patient-reported measures, and safety. The investigators designed this trial with the assistance of a digital twin-based clinical research system (termed X Town).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-70 years
  • Diagnosed type 2 diabetes
  • Stable medication regimen ≥ 3 months
  • HbA1c 7-10%
  • Smartphone access and ability to operate app
  • Willing to wear CGM and activity tracker
  • Able to provide informed consent

Exclusion criteria

  • Insulin therapy
  • Severe chronic/acute diabetic complications
  • Early-onset diabetes (<40 years at diagnosis)
  • Severe cardiovascular disease, uncontrolled hypertension, active liver disease, malignancy
  • Severe psychiatric or cognitive disorders
  • Allergy to CGM materials
  • Planned surgery or long-term travel during study

Treatment and study plan

Digital Lifestyle Therapeutic

Other

Personalized real-time lifestyle recommendations are delivered via via smartphone, tablet, etc., integrating glucose level and wearable data.

Standard Care

Behavioral

Participants receive standard diabetes management including medications and lifestyle recommendations based on guidelines.

Primary outcomes

  1. Time in Range (TIR, %)

    Time frame: Run-in period (Day -7 to Day 0) and intervention period (Day 1 to Day 28)

    Percentage of glucose readings within 3.9-10 mmol/L measured by CGM

Secondary outcomes

  1. Other CGM metrics

    Time frame: Run-in period (Day -7 to Day 0) and intervention period (Day 1 to Day 28)

    mean glucose, SD, CV, TAR (>10 mmol/L), TBR (<3.9 and <3.0 mmol/L), daytime/nighttime TIR, MAGE, MODD, AUC, etc.

  2. Patient-reported outcomes

    Time frame: Baseline and 28 days

    Using DDS, DSCS, Self-Efficacy, WHO-5 scales, etc.

  3. User Experience Score

    Time frame: At 28 days

    Evaluation in X Life group only. User experience will be assessed using a validated questionnaire covering usability, usefulness, satisfaction, and acceptability. Each item is rated on a 5-point Likert scale. Higher scores indicate better user experience.

  4. Safety outcomes

    Time frame: Day 1-28 (intervention period)

    Number of participants with CGM-recorded or symptomatic hypoglycemia (<3.9 mmol/L). Number of participants experiencing any AE/SAE.

  5. OGTT Glucose Concentration

    Time frame: Baseline and 28 days

    Plasma glucose at 0, 60, and 120 minutes during OGTT.

  6. OGTT Insulin Concentration

    Time frame: Baseline and 28 days

    Serum insulin at 0, 60, and 120 minutes during OGTT.

  7. OGTT C-peptide Concentration

    Time frame: Baseline and 28 days

    Serum C-peptide at 0, 60, and 120 minutes during OGTT.

  8. Body Weight

    Time frame: Baseline and 28 days

    Body weight (kg) measured using digital scale.

  9. Body Mass Index (BMI)

    Time frame: Baseline and 28 days

    Calculated as weight (kg) / height (m²).

  10. Waist Circumference

    Time frame: Baseline and 28 days

    Measured at the midpoint between the lowest rib and iliac crest.

  11. Hip Circumference

    Time frame: Baseline and 28 days

    Hip circumference measured at the widest part of the buttocks using a non-stretchable tape.

  12. Thigh Circumference

    Time frame: Baseline and 28 days

    Mid-thigh circumference measured at the midpoint between the inguinal crease and the proximal border of the patella.

  13. Systolic Blood Pressure

    Time frame: Baseline and 28 days

    Average of two seated measurements.

  14. Diastolic Blood Pressure

    Time frame: Baseline and 28 days

    Average of two seated measurements.

  15. Resting Heart Rate

    Time frame: Baseline and 28 days

    Measured by automated device after 5 minutes rest.

  16. Blood Lipids

    Time frame: Baseline and 28 days

    Total cholesterol, LDL-C, HDL-C, and triglycerides.

  17. Liver Function

    Time frame: Baseline and 28 days

    ALT, AST, GGT, etc.

  18. Kidney Function

    Time frame: Baseline and 28 days

    Serum creatinine, eGFR, etc.

  19. Inflammatory Markers

    Time frame: Baseline and 28 days

    C-reactive protein

  20. Composite Psychological and Behavioral Outcomes

    Time frame: Run-in end (Day 0), Intervention end (Day 28), Follow-up end (Day 35)

    Psychological and behavioral outcomes will be assessed using multiple validated questionnaires. Each scale will be reported and analyzed separately: Diabetes Distress Scale (DDS): 17 items, scored 1-6; higher scores indicate greater distress; General Self-Efficacy Scale (GSES): 10 items, scored 1-4, total 10-40; higher scores indicate stronger self-efficacy; WHO-5 Well-Being Index: 5 items, raw score 0-25 transformed to 0-100; higher scores indicate better well-being; Summary of Diabetes Self-Care Activities (SDSCA): Items scored 0-7 days per week; higher scores indicate better diabetes self-management behaviors.

Sponsors and collaborators

Lead sponsor

Li Huating

Other

Registry information

Acronym: X Life

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Sep 8, 2025
Registry last updated
Feb 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.